Risk and consequences of chemotherapy-induced thrombocytopenia in US clinical practice [PDF]
BMC Cancer, 2019 Background Chemotherapy-induced thrombocytopenia (CIT) is a potentially serious complication that can lead to chemotherapy dose delays, dose reductions, or discontinuation, and increases the risk of serious bleeding events.
Derek Weycker +6 more
doaj +5 more sources
Dose escalation study of an anti-thrombocytopenic agent in patients with chemotherapy induced thrombocytopenia [PDF]
BMC Cancer, 2010 Background Preclinical studies demonstrated that small chain RNA fragments accelerate the recovery of platelets numbers in animals exposed to high doses of chemotherapeutic drugs. There is anecdotal data supporting the same application in humans.
Hall John L +5 more
doaj +7 more sources
Chemotherapy-Induced Thrombocytopenia: Modern Diagnosis and Treatment [PDF]
British Journal of HaematologySummaryChemotherapy‐induced thrombocytopenia (CIT) is a common clinical problem in patients with solid tumour malignancies. Unlike nadir CIT which often resolves by the start of the following chemotherapy cycle, persistent CIT results in unacceptably low platelet counts at the beginning of a cycle lasting throughout multiple chemotherapy cycles ...
Hanny Al-Samkari, Andrew Song
exaly +4 more sources
Case Report: Oxaliplatin-Induced Immune-Mediated Thrombocytopenia [PDF]
Case Reports in Oncology, 2018 Thrombocytopenia is a frequent complication of cancer may be due to a variety of causes including malignancy itself, acute disease processes, or cancer therapy.
Elizabeth Pan +2 more
doaj +2 more sources
Romiplostim for management of chemotherapy-induced thrombocytopenia
Supportive Care in Cancer, 2014 Chemotherapy-induced thrombocytopenia (CIT) can cause delay or reduction in subsequent courses of chemotherapy. Here, we report on a series of 20 patients who had protracted CIT and were treated with romiplostim, a thrombopoietin receptor agonist.We performed a retrospective review of the use of romiplostim for dose-limiting CIT at Memorial Sloan ...
R, Parameswaran +6 more
openaire +3 more sources
Romiplostim Treatment of Chemotherapy-Induced Thrombocytopenia. [PDF]
J Clin Oncol, 2019 PURPOSE Chemotherapy-induced thrombocytopenia (CIT) leads to delay or reduction in cancer treatment. There is no approved treatment. METHODS We conducted a phase II randomized trial of romiplostim versus untreated observation in patients with solid tumors with CIT.
Soff GA +12 more
europepmc +4 more sources
CHEMOTHERAPY-INDUCED THROMBOCYTOPENIA LEADING TO LIFE-THREATENING HYPOVOLEMIC SHOCK IN CERVICAL CANCER: A CASE REPORT [PDF]
Jurnal Kedokteran DiponegoroHypovolemic shock due to acute hemorrhage is a life-threatening condition, particularly in cancer patients undergoing chemotherapy. Although recent studies have established protocols for managing hypovolemic shock in trauma and sepsis, the role of ...
Nurul Fadila +3 more
doaj +2 more sources
Avatrombopag for the treatment of patients with chemotherapy-induced thrombocytopenia: A case series. [PDF]
Br J HaematolSummaryManagement of chemotherapy‐induced thrombocytopenia (CIT) is challenging, often resulting in chemotherapy treatment delays, dose reduction, and treatment interruption. Randomized trials support the potential efficacy and safety of thrombopoietin receptor agonists in CIT management.
Galamaga R, Johnston S, Acosta C.
europepmc +4 more sources
Acute Immune-Mediated Thrombocytopenia due to Oxaliplatin and Irinotecan Therapy
Case Reports in Oncological Medicine, 2019 We describe a case of a 63-year-old woman with advanced colon cancer and liver metastases who was treated with fluorouracil, leucovorin, and oxaliplatin (FOLFOX) and cetuximab chemotherapy.
Eric L. Tam +3 more
doaj +2 more sources
Research Progress on Mechanism of Tumor-Associated Immune Thrombocytopenia [PDF]
Zhongliu Fangzhi YanjiuThrombocytopenia is a common complication during the treatment of malignant tumors. It can lead to insufficient doses of chemotherapy drugs or delayed chemotherapy, shorten patients’ survival time, and affect prognosis.
Guimin LIU +3 more
doaj +2 more sources